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Abstract
Drug addiction is an association of compulsive drug use with long-term associative learning/memory. Multiple forms of
learning/memory are primarily subserved by activity- or experience-dependent synaptic long-term potentiation (LTP) and
long-term depression (LTD). Recent studies suggest LTP expression in locally activated glutamate synapses onto dopamine
neurons (local Glu-DA synapses) of the midbrain ventral tegmental area (VTA) following a single or chronic exposure to
many drugs of abuse, whereas a single exposure to cannabinoid did not significantly affect synaptic plasticity at these
synapses. It is unknown whether chronic exposure of cannabis (marijuana or cannabinoids), the most commonly used illicit
drug worldwide, induce LTP or LTD at these synapses. More importantly, whether such alterations in VTA synaptic plasticity
causatively contribute to drug addictive behavior has not previously been addressed. Here we show in rats that chronic
cannabinoid exposure activates VTA cannabinoid CB1 receptors to induce transient neurotransmission depression at VTA
local Glu-DA synapses through activation of NMDA receptors and subsequent endocytosis of AMPA receptor GluR2
subunits. A GluR2-derived peptide blocks cannabinoid-induced VTA synaptic depression and conditioned place preference,
i.e., learning to associate drug exposure with environmental cues. These data not only provide the first evidence, to our
knowledge, that NMDA receptor-dependent synaptic depression at VTA dopamine circuitry requires GluR2 endocytosis, but
also suggest an essential contribution of such synaptic depression to cannabinoid-associated addictive learning, in addition
to pointing to novel pharmacological strategies for the treatment of cannabis addiction.
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Introduction
Cannabis (marijuana or cannabinoids) is the most commonly used
i l l i c i td r u gw o r l d w i d e[ 1 ]a n dt h el i f e t i m ep r e v a l e n c eo fc a n n a b i s
addiction is the highest of all illicit drugs in the United States [2].
However, there is no effective treatment for cannabis addiction in
humans, largely due to our poor understanding of its underlying
mechanism. The current view of drug addiction emphasizes an
association of compulsive drug use with molecular and cellular
mechanisms underlying long-term associative learning and memory
[3,4]. Ample evidence supports activity- or experience-dependent
long-term changes of synaptic strength, i.e., long-term potentiation
(LTP) and long-term depression (LTD), as the primary cellular
mechanisms underlying multiple forms of learning and memory [5].
Therefore, it would be of interest to examine the relationship of long-
t e r mc h a n g e so fs y n a p t i cs t r e n g t hw i t hd r u ga d d i c t i o ni nt h eb r a i n
circuitry critically involved in drug addiction, such as the midbrain
ventral tegmental area (VTA) where most drugs of abuse, including
cannabis, prominently increase the activity of its dopamine neurons
and thereby lead to drug rewarding response [6,7].
Stimulation of local excitatory afferents in the VTA activates
both postsynaptic AMPA receptor (AMPAR) and NMDA receptor
(NMDAR) in VTA dopamine neurons [8,9]. AMPAR consists of
GluR1–GluR4 subunits [10], whereas NMDAR is heteromeric
complex of NR1 subunit and at least one type of four NR2
subunits (NR2A–NR2D) [11]. Recent studies showed an induction
of NMDAR-dependent LTP at the locally activated glutamate
synapses onto VTA dopamine neurons (local Glu-DA synapses)
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amphetamine, morphine and ethanol [12,13] and facilitated LTP
induction at these synapses following chronic exposure to cocaine
[14] or when pairing of nicotine application with depolarizations
[15]. These reports suggest that LTP expression in VTA local Glu-
DA synapses following in vivo exposure of drugs of abuse may play
an important role in the development of drug addiction [12–15]. A
more recent study further demonstrated that a single exposure to
cocaine potentiated both VTA local Glu-DA synapses and
pedunculopontine nucleus-activated glutamate synapses onto
VTA dopamine neurons (PPN Glu-DA synapses) [16]. This
potentiation occurred through insertion of the higher conducting
GluR2-lacking AMPAR into both synaptic pathways, which
subsequently permitted expression of metabotropic glutamate
receptor (mGluR)-dependent LTD through reinsertion of the
lower conducting GluR2-containing AMPAR at these synapses
[16]. It is interesting to note that a single exposure of the major
psychoactive ingredient of marijuana, D9-tetrahydrocannabinol
(THC), induced GluR2-lacking AMPAR insertion into the PPN
Glu-DA synapses without significant effects on the local Glu-DA
synapses, thus permitting subsequent expression of mGluR-
dependent LTD through GluR2-containing AMPAR reinsertion
at the PPN Glu-DA synapses [16].
In summary, it is known that both a single and chronic exposure
to cocaine likely induces LTP at VTA local Glu-DA synapses [12–
14], which are generally believed to encode the powerful
glutamate afferent neurotransmission originating from the cerebral
cortex, especially the prefrontal cortex [17]. It is unknown,
however, whether chronic exposure of cannabinoids induces LTP
or LTD in VTA local Glu-DA synapses. More importantly,
whether such alterations in VTA synaptic plasticity causatively
contribute to drug addictive behavior has not previously been
addressed. To examine these issues, in the present study we
performed field potential recording of the EPSP (fEPSP) from the
VTA without any receptor antagonists for two reasons. First, field
potential recording of the EPSP, but not whole cell recording of
the excitatory postsynaptic current (EPSC), is able to provide the
essential information regarding overall change in excitatory afferent
synapses onto a population of various types of VTA neurons. Second,
the absence of any receptor antagonists during recording would
allow us to evaluate the overall influence of all receptors on
excitatory afferent synapses onto VTA neurons. To overcome the
potential problems of field potential recording (f.g., not able to
differentiate the type of cells expressing LTD/LTP), we further
conducted whole cell recordings of the EPSC from individual
dopamine and GABA neurons in the VTA. Finally, we explored
the mechanism underlying cannabinoid-induced changes in
synaptic strength in the VTA and its relation with cannabis-
associated addictive behavior by employing a combination of field
potential recordings and molecular, biochemical, immunohisto-
chemical and behavioral strategies.
Results
Cannabinoids Facilitate LTD Induction in the VTA via CB1
and NMDA Receptors
To determine the impact of cannabinoid on VTA synaptic
plasticity, we recorded the field EPSPs (fEPSPs) in midbrain slices
prepared from naı ¨ve rats and rats killed 24 h after chronic
injection (once daily injections for 5 days) of the cannabinoid
HU210 (100 mg/kg, i.p.) or vehicle. It has been shown that high-
frequency stimulation (HFS) and low-frequency stimulation (LFS)
of VTA local excitatory afferents induced LTP and LTD,
respectively, in the local Glu-DA synapses of naı ¨ve rats with the
presence of picrotoxin in the bath solution [8,17]. We observed
here that without picrotoxin in the bath solution, neither HFS
(100 Hz) nor LFS (1 Hz, 15 min) induced LTP or LTD in the
VTA of naı ¨ve rats (Figure 1A,B,F) or vehicle-treated rats
(100.366%, 100.164%, p.0.05 versus control, n=11). In
contrast, LFS induced LTD (72.364.3%, p,0.01 versus control,
n=22), but HFS still failed to induce LTP (100.267%, p.0.05
versus control, n=14), from HU210-treated rats (Figure 1C,D,F).
To explore whether other cannabinoids can also facilitate LTD
induction in the VTA, we examined THC (5 mg/kg, i.p.), the
major psychoactive ingredient of marijuana. Similar to HU210
injection, chronic THC injection also facilitated LFS-induced
LTD in the VTA (74.164.6%, p,0.01 versus control, n=11)
(Figure 1E,F).
Because both HU210 and THC are able to activate both
cannabinoid CB1 receptor (CB1R) and CB2 receptor, we further
determined the role of CB1R in cannabinoid-facilitated LTD
induction in the VTA. Daily pretreatment of rats with the selective
CB1R antagonist AM281 at the dose (3 mg/kg, i.p.) that blocked
cannabinoid action shown in our recent study [18], but not
vehicle, 20 min before daily HU210 injection prevented HU210-
facilitated LTD induction (10062.6%, p.0.05 versus control,
n=8) in the VTA (Figure 2A,E). We then examined LTD
induction after a selective knocking down of CB1R expression in
the VTA using CB1R shRNA expressed by adenoviral vectors.
After a bilateral injection of the vectors into the major part of the
VTA (Figure 2B), the CB1R shRNA, but not its scrambled
sequence, significantly suppressed CB1R expression in the VTA
(Figure 2C) and LFS-induced LTD in HU210-treated rats
(Figure 2D,E).
LTD induction can be divided into NMDAR-dependent and
NMDAR-independent LTD [5,19]. We first examined mGluR,
because cannabinoids induce LTD in the nucleus accumbens via
mGluR [20]. Bath application of vehicle or both the selective I/II
mGluR antagonist (RS)-a-ethyl-4-carboxyphenylglycine (CPPG,
10 mM) and II/III mGluR antagonist (RS)-a-cyclopropyl-4-
phosphonophenyl-glycine (4CPG, 10 mM) at concentrations that
block mGluR activity [21,22] failed to affect LTD induction in
HU210-treated rats (Figure 3A, 3E). In contrast, the selective
NMDAR antagonist AP-5 (50 mM) blocked LTD induction in
HU210-treated rats (98.162.3%, p.0.05 versus control, n=8)
(Figure 3B,E). NMDARs in adult brain are heteromeric complexes
of NR1 and NR2A or NR2B subunit. NVP-AAM077 (0.4 mM)
has been shown to completely block NR2A-containing NMDAR
and attenuate NR2B-containing NMDAR [23,24]. Ro25-6981
(1 mM) and ifenprodil (10 mM) have been shown to selectively
block NR2B-containing NMDAR [25,26]. We found that Ro25-
6981 (1 mM) or ifenprodil (10 mM), but not NVP-AAM077
(0.5 mM), blocked LFS-induced LTD (Figure 3C,D,E), suggesting
an involvement of NR2B-containing NMDAR in cannabinoid-
facilitated LTD induction in the VTA.
Cannabinoid Facilitates LTD Expression in VTA Dopamine
Neurons via AMPAR
Because local VTA glutamatergic afferents directly act on both
dopamine and GABA neurons, we employed whole cell recordings
to locate the VTA neurons for the expression of cannabinoid-
facilitated LTD. Dopamine and GABA cells were identified by the
presence and absence of a large (.50 pA) Ih current, respectively
[9]. Although a small number of VTA none-dopamine neurons
show a large Ih current [27], VTA GABAergic neurons do not
show a large Ih current. LFS to midbrain slices from rats receiving
chronic HU210 injection induced LTD in all putative dopamine
neurons examined (74.664.6%, p,0.01 versus control, n=6)
VTA Synaptic Depression in Cannabinoid Addiction
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(100.160.3%, p.0.05 versus control, n=8) (Figure 4B,D).
Cannabinoid-facilitated LTD in the VTA may therefore be
expressed in VTA dopamine neurons but not GABA neurons.
The last step of LTD expression involves facilitated endocytosis
of AMPAR GluR2 subunits [5,28–30], which can be selectively
blocked by a GluR2-derived peptide (
869YKEGYNVYG
877) [28–
30]. After rendering the peptide with cell-permeable by fusing it to
the cell-membrane transduction domain of the TAT protein
(YGRKKRRQRRR), the resulting TAT-GluR2 peptide is able to
disrupt both GluR2 endocytosis and LTD induction, without
significant effects on LTP induction [26,29]. The pivotal role of
GluR2 endocytosis in cannabinoid-facilitated LTD expression in
the VTA is supported by our findings that bath application of
TAT-GluR2, but not its scrambled sequence, blocked LTD
expression in HU210-treated rats (Figure 4C,D). GluR2 endocy-
tosis likely occurs in the postsynaptic membrane of VTA
dopamine neurons, instead of GABA neurons, because GluR2-
positive neurons were doubly stained with the dopamine-
synthesizing enzyme tyrosine hydroxylase (TH), but not with the
GABA-synthesizing enzyme glutamic acid decarboxylase 65/67
(GAD65/67) (Figure 4E). These results further support the idea
that the expression of cannabinoid-facilitated LTD in the VTA
occurs in dopamine neurons, but not in GABA neurons.
Cannabinoid Transiently Suppresses Synaptic
Neurotransmission in VTA Dopamine Neurons
While LFS induced VTA LTD at 24 h after chronic injection of
HU210 but not vehicle as shown above, LFS failed to induce LTD
at 30 min after either the fifth HU210 injection (99.263.4%,
p.0.05 versus baseline, n=16) (Figure 5A,E) or the fifth vehicle
injection (101.362.9%, p.0.05 versus baseline, n=7). These
results indicate the possible occlusion of LFS-induced LTD in vitro
at 30 min, but not at 24 h, by a preceding HU210-induced
synaptic depression in vivo. This working hypothesis is supported by
two additional experiments. First, VTA cell surface levels of
GluR2, but not GluR1 or GluR3, significantly reduced 30 min,
but not 24 h, after the fifth HU210 injection (n=3) (Figure 5B).
Second, the AMPAR/NMDAR ratio of glutamatergic synaptic
Figure 1. Cannabinoids facilitate LTD induction in the VTA. (A) HFS failed to induce LTP in naı ¨ve rat VTA. (B) LFS failed to induce LTD in naı ¨ve
rat VTA. (C) HFS failed to induce LTP from the VTA of HU210-treated rats. (D) LFS induced LTD from the VTA of chronic HU210-treated rats. (E) LFS
induced LTD from the VTA of chronic THC-treated rats. (F) Summary of LTD induction under various conditions. * p,0.01 versus baseline.
doi:10.1371/journal.pone.0015634.g001
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30 min (0.4460.05; n=10) than that at 24 h (0.7360.08; n=8)
after the fifth HU210 injection, that in naı ¨ve rats (0.6560.07;
n=10) and that in vehicle-treated rats (0.6760.06; n=8) while the
latter three were not significantly different from each other
(Figure 5C).
Our data together indicate that cannabinoid injection induces in
vivo synaptic depression in VTA dopamine neurons that lasts for
less than 24 h. To further test this hypothesis, we applied TAT-
GluR2 peptide to block HU210-induced LTD in vivo, and then
examined whether this blockade would result in prevention of
HU210-facilitated VTA LTD induction in vitro 24 h after the fifth
HU210 injection. Given that TAT-GluR2 peptide reaches peak
levels in the rodent brain at 100 min and is washed out of brain
within 8 h after a systemic injection [29], we injected TAT-GluR2
(1.5 mmol/kg, i.p.) 2 h prior to each daily HU210 injection. LFS
induced VTA LTD in rats receiving scrambled TAT-GluR2
peptide (83.766.3%, p,0.05 versus control, n=7), but not in rats
receiving TAT-GluR2 peptide (101.862.9%, p.0.05 versus
control, n=10) [Figure 5D,E]. Because GluR2 is located in
VTA dopamine neurons as shown above, these data further
support our hypothesis that HU210 induces in vivo transient
synaptic depression in VTA dopamine neurons.
Relation of Synaptic Depression and Cannabinoid
Addictive Behavior
To explore whether VTA synaptic depression causatively
contributes to cannabis addictive behavior, we examined the
effects of synaptic depression blockade with TAT-GluR2 on
HU210-induced conditioned place preference (CPP). Rats re-
ceived TAT-GluR2 or its scrambled sequence (1.5 mmol/kg, i.p.)
either at 2 h before each of four HU210 injections for conditioning
or at 22 h after conditioning. Scrambled peptide exerted no
significant effects on the acquisition of CPP (p,0.01 versus pre-
test, n=8), whereas TAT-GluR2 blocked the acquisition (p.0.05
versus pre-test, n=7), but not the expression (p,0.05 versus pre-
test, n=8), of HU210-elicited CPP (Figure 6A). To determine
Figure 2. VTA CB1R mediates cannabinoid-facilitated LTD induction in the VTA. (A) Systemic pretreatment with the selective CB1R
antagonist AM281 prior to daily HU210 injection blocked LFS-induced LTD in the VTA. (B) Localization of bilaterally microfusioned adenoviral vectors
containing GFP into the VTA. Scale bar: 150 mm. (C) Graph (top) and immunoblotting (bottom photos) show that CB1R shRNA (shRNA), but not its
scrambled sequence (Scrm), reduced CB1R expression in the VTA 2 and 5 days after intra-VTA injection. One-way ANOVA: F3,8=11.949, p,0.01.
* p,0.05, ** p,0.01 versus vehicle (LSD post hoc test). (D) Relative to scrambled shRNA (Scrm), CB1R shRNA (shRNA) infusion into the VTA inhibited
LFS-induced LTD in HU210-treated rats. (E) Summary of LTD induction following treatment with saline, AM281, scrambled shRNA (Scrm) or CB1R
shRNA (shRNA). One-way ANOVA: F7,70=14.853, p,0.001. * p,0.01, ** p,0.001 (LSD post hoc test) versus baseline or between Scrm+HU210 and
siRNA+HU210.
doi:10.1371/journal.pone.0015634.g002
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acquisition by its action in the VTA, we conducted intra-VTA
infusion of the peptide (15 pmol) 60 min before each HU210
injection during conditioning (Figure 6B). Consistent with our
hypothesis, intra-VTA infusion of TAT-GluR2 peptide, but not
scrambled peptide, blocked the acquisition of HU210-elicited CPP
(TAT-GluR2: p.0.05 versus pre-test, n=9; scrambled TAT-
GluR2: p,0.05 versus pre-test, n=9) (Figure 6C). Although
cannabinoids can suppress motor function, the impact of HU210
on CPP appears independent of the motor function, because
various treatments failed to affect locomotor activity on the testing
day (Figure 6D).
Discussion
A single injection of THC does not significantly affect synaptic
plasticity at the local Glu-DA synapses [16]. In the present study,
however we observed that chronic cannabinoid injection facilitat-
ed LFS-induced LTD, 24 h after the last cannabinoid exposure, at
these synapses in a NMDAR- and AMPAR GluR2 endocytosis-
dependent manner. Then, we hypothesized that cannabinoid
exposure induced VTA synaptic depression in living animals,
which lasts for less than 24 h. To support this hypothesis, we found
that LFS failed to induce VTA LTD at 30 min after the fifth
cannabinoid injection, indicating the occlusion of LFS-induced
LTD in vitro by a preceding cannabinoid-induced LTD in vivo.
Given that facilitated endocytosis of AMAPR GluR2 subunits is
the last step of LTD expression [5,19,28,29], our further
observation of a significant endocytosis of GluR2 in the VTA at
30 min after cannabinoid injection also support our hypothesis.
This hypothesis receives additional support by our findings
suggesting that a blockade of GluR2 endocytosis prior to
cannabinoid exposure with TAT-GluR2 prevented synaptic
depression in vivo, resulting in a blockade of cannabinoid-facilitated
in vitro LTD induction in the VTA.
AMPARs in inhibitory interneurons are devoid of GluR2
subunits in many brain regions such as the amygdala [31–34].
Here we provide the first evidence, to our knowledge, showing the
localization of GluR2 in VTA dopamine neurons, instead of
GABA neurons. Therefore, our findings of GluR2 endocytosis
following cannabinoid exposure in vivo suggest that cannabinoid-
induced in vivo synaptic depression occurs in VTA dopamine
neurons, but not in GABA neurons. This idea is further supported
by our whole cell recording experiments showing a significant
decrease in AMPAR/NMDAR ratio of local VTA glutamatergic
synaptic currents onto dopamine neurons 30 min following
cannabinoid injection, because an increased AMPAR/NMDAR
ratio of VTA glutamatergic synaptic currents onto dopamine
Figure 3. NMDAR mediates cannabinoid-facilitated LTD induction in the VTA. (A) CPPG and 4CPG together failed to affect LFS-induced LTD
in chronic HU210-treated rats. (B) AP-5 blocked LFS-induced VTA LTD in chronic HU210-treated rats. (C) Ro25-6981 and ifenprodil blocked LFS-
induced VTA LTD in chronic HU210-treated rats. (D) NVP-AAM077 failed to affect LFS-induced LTD in chronic HU210-treated rats. (E) Summary of LTD
induction and blockade. ** p,0.01 versus baseline.
doi:10.1371/journal.pone.0015634.g003
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induced LTP in vivo in VTA dopamine neurons [12,13].
Recent studies showed that mGluR-dependent LTD at VTA
local Glu-DA synapses is distinct from that observed in the
cerebellum and hippocampus [35], in which LTD results from
AMPAR endocytosis [35,36], while mGluR-dependent LTD in
VTA dopamine neurons requires the exchange of GluR2-lacking
AMPARs for those containing this subunit [16,35]. In the present
study we provide the first evidence, to our knowledge, suggesting
that NMDAR-dependent LTD at VTA local Glu-DA synapses
requires GluR2 endocytosis.
Endocannabinoids induce LTD via retrograde signalling from
postsynaptic induction to presynaptic expression: postsynaptically
released endocannabinoids act on presynaptic CB1R to induce
presynaptic LTD via reduced release probability [19,37,38]. Thus,
HU210 injection should induce a LTD that is expressed
presynaptically via reduced glutamate release, as supported by a
recent study showing that cannabinoids produce presynaptic
inhibition of glutamatergic transmission onto VTA dopamine
neurons [39]. It remains to be determined whether cannabinoid
induces in vivo transient synaptic depression in VTA dopamine
neurons through pre-, postsynaptic, or both mechanisms.
Wang’s group shows that TAT-GluR2 peptide disrupted stress-
induced impairment of spatial memory retrieval [26], amphet-
amine sensitization behavior [29], fear extinction [40], both
GluR2 endocytosis and LTD induction, without significant effects
on LTP induction, in the hippocampus [26] and nucleus
accumbens [29]. Other three groups also show that the same
peptide blocked fear conditioning-elicited LTD induction in the
amygdala and fear extinction [41,42], GluR2 endocytosis and
decreased AMPAR/NMDAR ratio in the prefrontal cortex and
cue-induced relapse to heroin seeking [43]. TAT-GluR2 produces
no significant effects on basal synaptic transmission [29], which is
in agreement with the specific role of the peptide in blocking
regulated AMPAR endocytosis and hence the expression of LTD
[28]. TAT-GluR2 produces no significant effects on motor
activity, motivation to respond to amphetamine [29], or
anxiogenic action [40]. TAT-conjugated peptides have been
consistently shown to penetrate through the blood-brain-barrier
and cell membrane so as to get into cells of all brain regions after a
systemic administration [29,44,45]. Therefore, in the present study
we utilized TAT-GluR2 for a selective disruption of LTD
induction in both electrophysiological experiments and behavioral
tests.
CPP produced by drugs of abuse results both from their direct
rewarding effects and from their capacity in promoting learning to
associate drug exposure with environmental cues [46]. The latter
process, but not the innate rewarding response, requires long-term
Figure 4. Dopamine neurons express cannabinoid-facilitated LTD in the VTA. (A) LFS induced a LTD from a VTA dopamine neuron (DA) in
chronic HU210-treated rats. (B) LFS did not induce LTD from a VTA GABA neuron (GABA) in chronic HU210-treated rats. (C) TAT-GluR2 peptide, but
not scrambled TAT-GluR2 peptide, prevented VTA LTD induction in HU210-treated rats. (D) Summary of LTD induction and blockade under various
conditions. * p,0.01 versus baseline. (E) Confocal microscopic images show that GluR2-immunoreactive neurons (red) were doubly stained (yellow)
with TH (green), but not with GAD65/67 (green). Scale bar: 25 mm.
doi:10.1371/journal.pone.0015634.g004
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Thus, blockade of HU210-elicited CPP by TAT-GluR2 may
represent its disruptive effects on learning to associate cannabinoid
exposure with environmental cues. While numerous studies have
reported long-term changes of synaptic strength at glutamatergic
afferents onto VTA dopamine neurons [12–17,35,36], it is entirely
unknown whether and how such changes in VTA synaptic
plasticity causatively contributes to drug-associated addictive
behavior. The present study provide the first direct evidence, to
our knowledge, suggesting the causative role of AMPAR
endocytosis-mediated transient synaptic depression at VTA local
Glu-DA synapses in cannabinoid-associated addictive learning.
A single exposure to cocaine potentiated both VTA local Glu-
DA synapses and PPN Glu-DA synapses through insertion of the
higher conducting GluR2-lacking AMPAR into both synaptic
pathways, which subsequently permitted expression of mGluR-
dependent LTD through reinsertion of the lower conducting
GluR2-containing AMPAR at these synapses [16]. However, a
single exposure to THC induced GluR2-lacking AMPAR
insertion into the PPN Glu-DA synapses without significant effects
on the local Glu-DA synapses, thus permitting subsequent
expression of mGluR-dependent LTD at the PPN Glu-DA
synapses but not the local Glu-DA synapses [16]. This report also
showed input-specificity for the baseline capacity for LTD at the
PPN Glu-DA synapses and local Glu-DA synapses, indicating
distinct roles played in each synaptic pathway. It remains to be
determined whether and how cannabinoid-potentiated synaptic
strength at VTA PPN Glu-DA synapses contribute to cannabinoid
addictive behavior.
Similar to other drugs of abuse, cannabinoid is able to activate
dopamine neuron [6,7] and thus, a logical expectation is that all
drugs of abuse would induce addiction through LTP induction in
VTA dopamine neurons. In our pilot study HU210 (100 mg/kg,
i.p.), which induced VTA LTD, failed to produce CPP in different
strains of rats. Considering that rats resumed normal spatial
learning at 24 h after the fifth daily HU210 injection (100 mg/kg,
Figure 5. Cannabinoid likely induces in vivo LTD in VTA dopamine neurons. (A) LFS did not induce LTD 30 min after the fifth HU210
injection. (B) A selective decrease of surface/whole cell ratio of GluR2 occurred 30 min, but not 24 h, after the fifth HU210 injection, relative to vehicle
treatment (n=3). * p,0.05 versus vehicle. (C) The top panel shows sample EPSCs in neurons from naive animals, animals killed 30 min after vehicle
injection or animals killed 30 min or 24 h after the fifth daily HU210 injection; the graph shows peak AMPAR- and NMDAR-mediated EPSCs expressed
as a ratio. One-way ANOVA: F3,32=4.471, p,0.05. * p,0.05 versus naı ¨ve, vehicle or 24 h. (D) Pretreatment with TAT-GluR2, but not scrambled TAT-
GluR2, disrupted LFS-induced LTD in VTA slices prepared 1 day after the fifth HU210 injection. (E) Bar graphs summarize data shown in A and D.
* p,0.05 versus baseline. HU210 (30 min), midbrain slices were prepared 30 min after the final HU210 injection; sTAT-GluR2, scrambled TAT-GluR2.
doi:10.1371/journal.pone.0015634.g005
VTA Synaptic Depression in Cannabinoid Addiction
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15634i.p.) [47], the findings in our pilot study may result from HU210-
induced memory impairment effects during the first 4 days. We
therefore modified protocol: rats were placed in their home cages
after each of 4 daily priming HU210 injections; 24 h after the 4th
priming injection, four conditioning pairs were conducted by
placing rats in the non-preferred compartments for 30 min after
HU210 injection. With this protocol we observed consistent CPP
following HU210 injection. The CPP observed is unlikely
produced by the anxiolytic effects of HU210 (100 mg/kg, i.p.)
because this high dose of HU210 produce anxiogenic-like effects
[48], although we cannot exclude the possibility that the CPP
observed may be produced by the removal of some sort of
conditioned place aversion. This protocol is different from other
protocols for establishing rat CPP with other drugs of abuse, in
which both 4-day prime training and 4-day conditioning in non-
preferred environment are not required. Therefore, the develop-
ment of cannabis-associated addictive learning, i.e. the learning to
associate cannabis exposure with environmental cues, is different
from the development of addictive behavior induced by other
drugs of abuse.
Our data suggest that cannabinoid exposure induces in vivo
transient synaptic depression in VTA dopamine neurons, but
previous reports indicate that nicotine, cocaine, amphetamine,
morphine and ethanol may induce LTP in these neurons [12–15].
If these drugs of abuse produce addictive behavior through VTA
LTP, co-administration of cannabinoid and one of these drugs of
abuse may neutralize their opposite effects on VTA synaptic
plasticity and thereby block their individual addictive behavior
during the development stage of drug addiction. This idea is
supported by the findings that the cannabinoid WIN 55,212-2
inhibited cocaine addictive effects [49,50]. However, recent studies
indicate that cannabinoid may enhance or aggravate sensitization
and relapse to other drugs of abuse because GluR2 endocytosis-
dependent LTD may also be required for these processes. Thus,
the same TAT-GluR2 peptide used in the present study to disrupt
LTD induction prevented amphetamine-induced behavioral
sensitization [29] and attenuated cue-induced relapse to heroin-
seeking [43]; HU210 provoked relapse to cocaine seeking after
prolonged periods of cocaine withdrawal [51].
Conclusions
Our primary findings suggest that chronic cannabinoid
exposure is able to alter long-term synaptic strength at VTA local
Glu-DA synapses, although a recent study reveals no significant
changes of synaptic plasticity at these synapses following a single
exposure to cannabinoid [16]. While mGluR-dependent LTD in
Figure 6. Blockade of HU210-elicited CPP by TAT-GluR2 peptide. (A) Systemic injection of TAT-GluR2 peptide, but not its scrambled version
(sTAT-GluR2), blocked the acquisition, but not the expression (ex), of HU210-elicited CPP. One-way ANOVA: F9,72=3.132, p,0.01. * p,0.01 versus pre-
test. (B) Diffusion of the fluorescent dansyl-TAT-GluR2 in the VTA after intra-VTA injection. Diagram (left) illustrates the diffusion area shown in the
fluorescent image (middle). The right photograph shows peptide transduction in individual VTA neurons. ml, medial lemniscus. Scale bars: 400 mm
(middle) or 25 mm (right). (C) Bilateral intra-VTA injection of TAT-GluR2 (n=9), but not scrambled peptide (sTAT-GluR2; n=9), blocked HU210-elicited
CPP (left graph). * p,0.05 versus pre-test. The right histograms show reconstructions of histology sections illustrating VTA injection sites. (D) Effects
of various treatments on locomotor activity. Animals receiving various treatments did not show significant difference in locomotor activity on the
testing day, i.e. the total distance traveled in all 3 compartments (one-way ANOVA, F5,43=1.000, p=0.430) and total entry times to each compartment
(one-way ANOVA, F5,43=0.164, p=0.975).
doi:10.1371/journal.pone.0015634.g006
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AMPARs for those containing this subunit [16,35], we demon-
strate here that NMDAR-dependent LTD in VTA dopamine
circuitry requires GluR2 endocytosis. More importantly, while it is
unknown whether alterations in synaptic plasticity in VTA
dopamine circuitry causatively contribute to drug addictive
behavior, our findings strongly suggest a pivotal role of LTD in
VTA dopamine circuitry in the development of cannabinoid-
associated addictive learning. In addition, the present study
indicates a novel therapeutic strategy for treating cannabis
addiction with the TAT-GluR2 peptide.
Materials and Methods
Animal Treatment
All procedures were performed in accordance with the
guidelines established by the Canadian Council on Animal Care
as approved by Animal Care Committee of the University of
Ottawa Institute of Mental Health Research (IMHR ACC).
Specifically, the IMHR ACC approved the present study (ACC-
2007-001). Male Sprague-Dawley rats (16–92 days, Charles River)
were employed, with young rats used for major part of field
potential recording and all whole cell recording experiments and
adult rats for some of field potential recording experiments and all
molecular/biochemical, immunnohistochemical and behavioral
studies. Because the amplitude of synaptic depression recorded
from young rats is significantly higher than that from adult rats
following chronic HU210 injection, as illustrated by Figures 1
(young rats) and 2 (adult rats), data comparison was done only
between young or adult rats and the same control groups were
used in both young and adult rats. Rats received no treatment
(naı ¨ve rats) or once daily injections for 5 days of HU210 (100 mg/
kg, i.p.), THC (5 mg/kg, i.p.), or vehicle. In some cases, AM281
(3 mg/kg, i.p.) and TAT-GluR2 peptide (1.5 mmol/kg, i.p.) or
scrambled TAT-GluR2 peptide was injected 20 min (AM281) or
2 h before HU210 injection. Intra-VTA cannulation was
conducted under isoflurance anesthesia. Rats received bilateral
cannulae (26 Ga) implantation into the VTA (25.8 AP, +0.75 ML,
27.5 DV), and then cannula were secured to the skull. One week
later, adenoviral vectors (10
10 plaque-forming units/ml/side, a
single infusion 1 day before the first daily HU210 injection) or a
dansyl tagged TAT-GluR2 peptide (15 pmol in 0.6 ml) was
injected into the VTA. The diffusion regions of adenoviral vectors-
containing green fluorescent protein (GFP) and Dansyl-TAT-
GluR2 were examined after perfusion rats transcardially and
cutting brain sections as described [18,52].
Electrophysiology
The VTA fEPSPs were recorded as described [17]. Briefly, rats
anaesthetized with chloral hydrate were decapitated 30 min or
24 h after the last injection of HU210 or vehicle. A block of tissue
containing midbrain was rapidly removed into ice-cold low-
calcium artificial cerebrospinal fluid (ACSF) containing (in mM):
126 NaCl, 2.5 KCl, 1.2 NaH2PO4, 1.2 MgSO4, 0.625 CaCl2, 21.4
NaHCO3, 11.1 glucose, with 0.4 ascorbic acid added. Horizontal
slices (320 mm) were cut with a vibrotome and stored for at least
1 h at 35uC in the standard ACSF (i.e., containing 2.4 mM CaCl2)
with 0.4 mM ascorbic acid added. Slices were transferred into
recording chamber (30–32uC) and continuously perfused with the
standard ACSF at 1.5–2.0 ml/min. Extracellular and whole cell
recordings from the VTA were performed with a Multiclamp
700B amplifier (Axon Instruments). Both fEPSP and EPSC were
evoked at 0.05 Hz with a concentric bipolar electrode (FHC)
placed 100–300 mm (for extracellular recording) or 50–100 mm
(for intracellular recording) rostral to the recording site. Stimulus
pulse intensities were typically 0.3–1.5 mA with duration of 300 ms
for fEPSP or 100 ms for EPSC. For extracellular recording, a glass
microelectrode was filled with 2 M NaCl. For whole-cell
recordings with perforated patch, individual cells in the VTA
were visualized using infrared-differential interference contract.
For whole cell LTD recording, patch pipettes (4–7 MV) were filled
with a solution containing (in mM): 140 potassium gluconate, 5
KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 MgATP, 0.3 Na2GTP
and 10 Na2-phosphocreatine, with pH 7.2 (adjusted by KOH.
1 mg/ml). Perforated-patch was performed by adding DMSO-
dissolved amphotericin B into the internal solution, and neurons
were voltage-clamped at 270 mV. Dopamine and GABA cells
were identified by the presence and absence of a large (.50 pA) Ih
current, respectively, in response to a hyperpolarizing pulse to
2110 mV upon break in [9]. Because the presence of a large Ih
current does not exclusively belong to dopamine neurons [27],
putative dopamine neurons in our study may contain some non-
dopamine neurons. LTP was induced with HFS at 100 Hz for
1 sec and this train was repeated twice, 20 s apart. LTD was
elicited with LFS at 1 Hz for 15 min. Levels of LTP or LTD are
reported as a comparison of average EPSC or fEPSP amplitudes
for a 10 min time period immediately before LTP or LTD
induction with those during the 10 min period from 40 to 50 min
after HFS or LFS [17,53]. To measure the AMPAR/NMDAR
ratio, the intracellular solution contained (in mM): 120
CsCH3SO3, 20 HEPES, 0.4 EGTA, 2.8 NaCl, 5 TEA-Cl, 2
MgCl2, 2.5 MgATP, 0.3 GTP (pH 7.2 with CsOH); dopamine
neuron was voltage-clamped at +40 mV. After a stable baseline
recording of total EPSCs, the NMDAR antagonist DL-2-Amino-
5-phosphonopentanoic acid (AP-5, 50 mM) was applied in the bath
for 5–10 min to isolate fast AMPAR-mediated EPSCs, and digital
subtraction of AMPAR-EPSCs from the total EPSCs from the
same neuron yielded NMDAR-EPSCs.
Adenovirus Preparation and in vivo Gene Silencing
The oligonucleotides encoding scramble or rat CB1-targeted
shRNAs were synthesized, annealed and ligated into the GFP-
expressing adenoviral shuttle vector pAdshRNA/H1 [54]. The
targeting sequences of shRNAs are as follows: CB1-1, 59-
GATGAACAAGCTTATCAAG-39 and CB1-2, 59-CTGCAA-
GAAGCTGCA ATCT-39; scramble, 59-GAGAGTACTACGAT-
CATAA-39. Recombinant adenoviruses were prepared using the
pAdEasy system [55]. After intra-VTA microinfusion of adenovi-
ral vectors, the VTA was dissected for the quantification of CB1R
protein using immunoblotting procedures described below.
Transduction of VTA cells by recombinant adenoviruses was
determined by GFP reporter coexpressed by the vector.
Immunofluorescent Staining
Using protocol described [52], rats were perfused with 4%
paraformaldehyde and brains were cut into frontal sections (40-mm
thick), which were then incubated in a cocktail solution containing
mouse anti-GluR2 antibody (1:100; Chemicon) and sheep anti-
TH antibody (1:100; Chemicon) or rabbit anti-GAD65/67
antibody (1:100; Chemicon) for 3 days. After washing, the sections
were incubated in another cocktail solution containing Alexa Fluor
568-conjugated goat anti-rabbit (1:500, Molecular Probes) and
Alexa Fluor 488-conjugated goat anti-mouse (1:500, Molecular
Probes) or donkey anti-sheep (preabsorbed with goat IgG)
secondary antibodies (1:1000, Molecular Probes) at room
temperature for 4 h. For GFP single imuunohistochemical
labeling, GFP was visualized with mouse anti-GFP antibody
(1:2000, Sigma). Sections were examined with 106 or 606 lens
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META).
Surface AMPAR Measurement
Biotinylation experiments were performed with modifications of
the recent protocols [56,57]. Briefly, after incubation in ACSF
containing 1 mg/ml of Sulfo-NHS-SS-Biotin (Pierce) for 30 min,
midbrain slices were rinsed 3 times and then homogenized in
500 ml of lysis buffer (1% triton-X100, 0.1% SDS, 50 mM Tris
pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5 mM AEBSF, 50 mM
Antipain HCl, 25 mM leupeptine and 0.5 mg/ml pepstatin),
followed by centrifugation at 14,0006g for 15 min at 4uC. While
25 ml of biotinylated proteins were used as the ‘‘total’’ fraction,
50 ml of streptavidin beads (Sigma) were added to 100 mgo f
biotinylated VTA proteins and incubated overnight at 4uC. After
washing, biotinylated proteins were eluted off the beads using
40 mlo f2 6 SDS-PAGE loading buffer. Then, immunoblotting
was conducted as described below.
Immunoblotting
Immunoblotting was conducted as described [52]. Briefly,
membranes were probed with primary antibodies to GluR1
(1:250, Upstate), GluR2 (1:500, Chemicon), GluR3 (1:200,
Chemicon) or CB1R (1:500, Santa Cruz Biotechnology) overnight
at 4uC. Immunoreactive bands were visualized using enhanced
chemiluminescence and captured by a CCD digital camera. Bands
were analyzed by densitometry (Alpha Innotech). Receptor ratio
for AMPAR subunits was determined by dividing the surface
intensity by the total intensity.
Behavioral Tests
The place preference system (TSE Systems, Inc., Midland,
USA) consisted of 3 distinct chambers with non-transparent walls.
CPP was conducted with modifications of our recent protocol
[52]. Briefly, CPP took place over preconditioning, priming
(HU210 only), conditioning and postconditioning phases. During
preconditioning, which was conducted by allowing rats to have
free access to 3 chambers for 15 min per day for 1 or 2 days, the
environment was adjusted to allow rats to stay in one choice
chamber for longer time (i.e. the preferred chamber) than the
other choice chamber (i.e. the none-preferred chamber). During
priming phase rats were placed in their home cages for 1 day
immediately after each daily injection of HU210 (100 mg/kg, i.p.)
for 4 days. For the conditioning, which was conducted 24 h after
the last HU210 injection for cannabinoid priming, four pairings
with drug and four pairings with vehicle were conducted once
daily for 8 days. Ten min after an i.p. injection of HU210 (100 mg/
kg) or vehicle (HU210:DMSO:TWEEN 80:saline=1:1:8), rats
were placed in the none-preferred conditioning compartment for
30 min, with the gateway closed. On alternative days, all groups of
rats were given vehicle injection and then placed in the preferred
compartment for 30 min, with the gateway closed. For study the
effects of TAT-GluR2 one the acquisition of CPP, rats received
i.p. or bilateral intra-VTA injections of TAT-GluR2 peptide or
scrambled TAT-GluR2 peptide 1 h (15 pmol/0.6 ml/side, intra-
VTA) or 2 h (1.5 mmol/kg, i.p.) before HU210 injection (100 mg/
kg, i.p.). All intra-VTA injections were administered in a volume of
0.6 ml/side. On alternative days, rats received double injections of
appropriate vehicle (saline for the peptide). The postconditioning
was conducted exactly as in the preconditioning, i.e. free access to
each compartment for 15 min, during which the time spent by
each rat in the none-preferred compartment was recorded. The
time spent by each rat in the none-preferred compartment during
the preconditioning and postconditioning was compared, with
higher and lower values in post-test indicating CPP and
conditioned place aversion, respectively. For study the effects of
TAT-GluR2 on the expression of CPP, rats received an i.p.
injection of TAT-GluR2 peptide or scrambled TAT-GluR2
peptide 2 h (1.5 mmol/kg, i.p.) before the postconditioning. The
total distance traveled in all 3 compartments and total entry times
to each compartment during postconditioning were recorded for
measuring locomotor activity. After postconditioning, rats receiv-
ing intra-VTA injections were perfused transcardially and brain
sections were stained with cresyl violet for verification of cannula
placement.
Data Analysis
Results were reported as mean 6 SE. Statistical analysis of the
data was performed using a student t test, one-way ANOVA or
one-way ANOVA for repeated measures, followed by Fisher’s
LSD post hoc test. Statistical significance was set at p,0.05.
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